Evidence map›Paper›PMID 33827515›Full record

SynthesisBMC complementary medicine and therapies2021

Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review.

L Susan Wieland, Vanessa Piechotta, Termeh Feinberg, Emilie Ludeman, Brian Hutton, Salmaan Kanji, Dugald Seely, Chantelle Garritty

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in BMC complementary medicine and therapies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. A standardized combination ofFood & nutrition research · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

L Susan WielandCenter for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. swieland@som.umaryland.edu.ORCID http://orcid.org/0000-0003-2157-0603
Vanessa PiechottaEvidence-based Oncology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Termeh FeinbergKelly Government Solutions, Rockville, MD, USA.
Emilie LudemanUniversity of Maryland, Health Sciences and Human Services Library, Baltimore, MD, USA.
Brian HuttonThe Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
Salmaan KanjiThe Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
Dugald SeelyThe Ottawa Hospital, Ottawa, Ontario, Canada.
Chantelle GarrittyThe Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
Ottawa Hospital · CAUniversity of Maryland, Baltimore · USCanadian College of Naturopathic Medicine · CAUniversity of Cologne · DEUniversity of Ottawa · CAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Cochrane Complementary Medicine Field: Resource for ResearchR24AT001293 · NCCIH · UNIVERSITY OF MARYLAND BALTIMORE · PI BERMAN, BRIAN M, WIELAND, LISA SUSAN · 2003 to 2022
$9.4M
NCATS NIH HHS UL1 TR001863NCCIH NIH HHS R24 AT001293
6 · The paper itself

Abstract

backgroundElderberry has traditionally been used to prevent and treat respiratory problems. During the COVID-19 pandemic, there has been interest in elderberry supplements to treat or prevent illness, but also concern that elderberry might overstimulate the immune system and increase the risk of 'cytokine storm'. We aimed to determine benefits and harms of elderberry for the prevention and treatment of viral respiratory infections, and to assess the relationship between elderberry supplements and negative health impacts associated with overproduction of pro-inflammatory cytokines.

methodsWe conducted a systematic review and searched six databases, four research registers, and two preprint sites for studies. Two reviewers independently assessed studies for inclusion, extracted data from studies, assessed risk of bias using Cochrane tools, and evaluated certainty of estimates using GRADE. Outcomes included new illnesses and the severity and duration of illness.

resultsWe screened 1187 records and included five randomized trials on elderberry for the treatment or prevention of viral respiratory illness. We did not find any studies linking elderberry to clinical inflammatory outcomes. However, we found three studies measuring production of cytokines ex vivo after ingestion of elderberry. Elderberry may not reduce the risk of developing the common cold; it may reduce the duration and severity of colds, but the evidence is uncertain. Elderberry may reduce the duration of influenza but the evidence is uncertain. Compared to oseltamivir, an elderberry-containing product may be associated with a lower risk of influenza complications and adverse events. We did not find evidence on elderberry and clinical outcomes related to inflammation. However, we found evidence that elderberry has some effect on inflammatory markers, although this effect may decline with ongoing supplementation. One small study compared elderberry to diclofenac (a nonsteroidal anti-inflammatory drug) and provided some evidence that elderberry is as effective or less effective than diclofenac in cytokine reduction over time.

conclusionsElderberry may be a safe option for treating viral respiratory illness, and there is no evidence that it overstimulates the immune system. However, the evidence on both benefits and harms is uncertain and information from recent and ongoing studies is necessary to make firm conclusions.

Indexed as

COVID-19 Drug TreatmentPhytotherapySambucusCommon ColdCOVID-19CytokinesHumansInflammationInfluenza, HumanPandemicsPlant ExtractsSARS-CoV-2CytokinesPlant ExtractsCOVID-19CytokinesElderberryInflammationRespiratory illnessSambucusSystematic reviewViral illness

Identifiers

PMID33827515
PMCPMC8026097
OpenAlexW3142270069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.